ArticleJournal of advanced research2026
CCR1
Article in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Insights into the pathogenesis of rheumatic and immune diseases from single-cell omics.Frontiers in immunology · 2026Pooled it
- Migration of immune cells in tumors and inflammation: molecular mechanisms and therapeutic targets.Signal transduction and targeted therapy · 2026Review
- A Mouthful of Genomic Data: Single-Cell Insights into Salivary Gland Biology and Disease.Biology · 2026Review
- Wnt/β -catenin signalling shapes macrophage behaviour during injury and repair in the mouse submandibular gland.Scientific reports · 2026Article
- Characteristics of peripheral blood neutrophil subsets in patients with primary Sjogren's syndrome based on single-cell RNA sequencing.Frontiers in immunology · 2026Article
- Macrophage polarization in Sjögren's syndrome: from mechanisms to therapeutic translation.Frontiers in immunology · 2026Review
- CD74Journal of translational medicine · 2025Article
- Salivary gland cell senescence in Sjögren's syndrome: current research and novel therapeutic directions.Immunity & ageing : I & A · 2025Review
- Review
- Salivary gland macrophages in health and disease: heterogeneity, niche crosstalk, and therapeutic avenues.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCCR1 upregulation in macrophages promotes sequential T/B-cell infiltration via CCL5-mediated crosstalk, aggravating salivary gland damage in Sjögren's syndrome (SS), implicating CCR1/CCL5 as potential therapeutic targets.
objectivesTo investigate the role of CCR1/CCL5 in salivary gland lymphocytic infiltration and SS progression.
methodsFunctional enrichment analysis was performed on four bulk RNA-seq datasets to identify common immune pathways, highlighting CCR1 as a key factor. Cytohubba and STRING analyses identified CCL5 as the primary ligand for CCR1 in SS salivary glands. Single-cell RNA sequencing (scRNA-seq) and temporal analyses were performed for the cellular distribution of CCR1 and CCL5, their interactions, and sequential immune cell infiltration, and further validated using multiplex immunofluorescence (mIF) in SS patients and Non Obese Diabetes (NOD) mice salivary glands. The effect of CCR1 inhibition on SS progression was assessed in NOD mice.
resultsWe observed CCR1 overexpressed (CCR1
conclusionWe revealed that CCR1
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.